Bayesian Health, an AI and machine learning platform, launched Monday with an accompanying study revealing faster recognition and treatment times for patients.
A new clinical AI platform launched Monday with the goal of helping "physicians make the best care decisions, faster."
Bayesian Health launched alongside an adoption and utilization study which found faster recognition and treatment times and a 90% adoption rate.
"Having spent over two decades in AI and machine learning research, I know there’s immense potential to create AI tools to drive better care outcomes," founder and CEO of Bayesian Health, Suchi Saria, PhD, said in a media release. "Health data are messy, and it requires deep AI expertise to deliver strategies that can successfully analyze this data … We’re doing it differently, being one of the first solutions to deliver accurate and actionable clinical signals that physicians and nurses are actually acting upon."
The AI tool spent more than three years in development at John Hopkins University, and uses patents, peer-reviewed research, and technology licensed from the University.
The platform sits within the electronic medical record (EMR) systems and analyzes patient data to create actionable clinical signals to help physicians and clinicians accurately diagnose and deliver timely care, with modules for clinical deterioration, sepsis, pressure injury, and transitions of care.
A recent study found a 1.85 hour faster antibiotic treatment rate for sepsis in the sepsis module, decreasing mortality rates. Another study found a 14% reduction in ICU admissions, a 12% reduction in ICU length of stay, and a 10% reduction in supportive therapy needs.
Bayesian Health has raised $15 million in venture funding led by Andreessen Horowitz, which led Bayesian Health's venture funding, raised $15 million. Health 2047 Capital Partners, Lifeforce Capital, and Catalio Investments also participated in funding.
"The number of data points being generated every single day for any given patient in a hospital is enormous and continues to rise. And yet most physicians have never interacted with any AI technology that actually helps them analyze these data, or gives them any clinical insights," General Partner at Andreessen Horowitz and internal medicine physician, Vineeta Agarwala MD, PhD, said in a statement. "Early results from the real-world use of Bayesian Health's platform is showing us that it can fit into our workflow, and augment how clinicians triage and diagnose patients."
Melanie Blackman is the strategy editor at HealthLeaders, an HCPro brand.